ACARIX AB Financials Acarix AB Deutsche Boerse AG
Equities
7AC
SE0009268717
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0236 EUR | -16.90% |
|
-21.33% | +55.26% |
| 11/06 | Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study | CI |
| 27/05 | Acarix AB Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 65.91 | 167.1 | 219.7 | 71.81 | 139.9 | 338.2 | - | - |
| Enterprise Value (EV) 1 | 12.16 | 167.1 | 203.9 | 60.65 | 139.9 | 334.2 | 338.2 | 338.2 |
| P/E ratio | -0.7 x | -2.32 x | -2.36 x | - | -1.19 x | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 35.5 x | - | 58.4 x | 12.3 x | 22.4 x | 6.23 x | 1.91 x | 1.32 x |
| EV / Revenue | 6.55 x | - | 54.2 x | 10.4 x | 22.4 x | 6.15 x | 1.91 x | 1.32 x |
| EV / EBITDA | -0.29 x | - | -4.22 x | -0.83 x | -1.88 x | -9.8 x | 4.96 x | 3.32 x |
| EV / FCF | -0.27 x | - | -4.24 x | -0.81 x | -1.72 x | -6.43 x | -113 x | - |
| FCF Yield | -366% | - | -23.6% | -124% | -58.2% | -15.6% | -0.89% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 51,694 | 1,41,045 | 2,51,972 | 2,51,972 | 7,37,189 | 9,73,170 | - | - |
| Reference price 2 | 1.275 | 1.185 | 0.8720 | 0.2850 | 0.1898 | 0.3475 | 0.3475 | 0.3475 |
| Announcement Date | 20/02/20 | 20/04/21 | 17/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.857 | - | 3.76 | 5.822 | 6.241 | 54.3 | 176.6 | 256.1 |
| EBITDA 1 | -42.33 | - | -48.32 | -73.44 | -74.46 | -34.1 | 68.2 | 102 |
| EBIT 1 | -46.44 | - | -51.7 | -76.48 | -77.55 | -39.8 | 50.2 | 84.2 |
| Operating Margin | -2,501.02% | - | -1,374.89% | -1,313.55% | -1,242.64% | -73.3% | 28.43% | 32.88% |
| Earnings before Tax (EBT) 1 | -46.43 | - | -51.73 | -76.98 | -77.84 | -54 | 2 | - |
| Net income 1 | -46.46 | -41.5 | -51.73 | -76.98 | -77.84 | -54 | 2 | - |
| Net margin | -2,501.83% | - | -1,375.82% | -1,322.31% | -1,247.22% | -99.45% | 1.13% | - |
| EPS | -1.830 | -0.5100 | -0.3700 | - | -0.1600 | - | - | - |
| Free Cash Flow 1 | -44.53 | - | -48.05 | -75.02 | -81.37 | -52 | -3 | - |
| FCF margin | -2,398.12% | - | -1,277.93% | -1,288.56% | -1,303.73% | -95.76% | -1.7% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20/02/20 | 20/04/21 | 17/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.653 | 1.54 | 1.573 | 1.174 | 1.552 | 6.5 | 19 | 27.2 |
| EBITDA 1 | - | - | - | -16.43 | -21.28 | -14.22 | -13.8 | -4.4 | 1 |
| EBIT 1 | - | -22.61 | - | -17.23 | -22 | -14.93 | -15 | -6.2 | -1 |
| Operating Margin | - | -1,368% | - | -1,095.1% | -1,873.76% | -961.79% | -230.77% | -32.63% | -3.68% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | -21.11 | - | -22 | - | - | - | - | - | - |
| Net margin | - | - | -1,428.83% | - | - | - | - | - | - |
| EPS | -0.0800 | - | -0.0500 | -0.0400 | -0.0300 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 16/11/22 | 16/02/23 | 31/08/23 | 09/11/23 | 15/02/24 | 14/05/24 | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 53.7 | - | 15.9 | 11.2 | - | 4 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -44.5 | - | -48.1 | -75 | -81.4 | -52 | -3 | - |
| ROE (net income / shareholders' equity) | -56.5% | - | -56.6% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 1 | 2 | - |
| Capex / Sales | - | - | - | - | - | 1.84% | 1.13% | - |
| Announcement Date | 20/02/20 | 20/04/21 | 17/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
| 1st Jan change | Capi. | |
|---|---|---|
| -55.12% | 220.34Cr | |
| +19.59% | 183.44Cr | |
| -8.65% | 141.92Cr | |
| +17.35% | 118.5Cr | |
| -24.23% | 86Cr | |
| +1.25% | 78Cr | |
| -34.22% | 72Cr | |
| -29.27% | 59Cr | |
| +16.98% | 57Cr |
- Stock Market
- Equities
- ACARIX Stock
- 7AC Stock
- Financials Acarix AB
